Top
image credit: Unsplash

Novel cell reprogramming offers a promising therapeutic strategy to slow down glioblastomas

September 16, 2021

Gliomas are the most common primary brain tumors in adults. Among them, high-grade glioblastomas (GBMs) are particularly known to be notoriously aggressive and invasive, which makes it challenging to treat them. The disease rapidly progresses to an advanced stage in a short span of time, and the survival of such patients is often dismal.

Despite substantial research, targeted therapies that can improve the survival rate and quality of life of patients with GBM are lacking. Current therapies are focused on inhibiting tumor growth or destroying cancer cells. However, given the high adaptability, resistance, and diversity of these tumors, such therapies alone are insufficient.

Read More on The Medical News